Vall d'Hebron University Hospital Research Institute
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Migraine Disorders
Sumatriptan
There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication. There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment. The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan. Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 108 participants |
| Official Title : | Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I |
| Actual Study Start Date : | 2024-01-25 |
| Estimated Primary Completion Date : | 2024-12 |
| Estimated Study Completion Date : | 2024-12 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 45 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Vall d'Hebron University Hospital
Barcelona, Spain,